Chelsea Therapeutics International Ltd.  

(Public, NASDAQ:CHTP)   Watch this stock  
Find more results for CHTP
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.28
Shares 78.70M
Beta     -
Inst. own 48%
Aug 4, 2014
Q2 2014 CHELSEA THERAPEUTICS Earnings Release (Estimated) Add to calendar
Jun 9, 2014
CHELSEA THERAPEUTICS Annual Shareholder Meeting (Estimated)
May 9, 2014
Q1 2014 CHELSEA THERAPEUTICS Earnings Release
May 8, 2014
CHELSEA THERAPEUTICS Conference Call to Discuss Acquisition by Lundbeck
May 8, 2014
H. Lundbeck A/S to Acquire Chelsea Therapeutics International Ltd Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -74.99% -43.53%
Return on average equity -81.83% -47.47%
Employees 19 -
CDP Score - -

Address

3530 Toringdon Way Ste 200
CHARLOTTE, NC 28277-3436
United States - Map
+1-704-3411516 (Phone)
+1-302-6365454 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson´┐Żs Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.